查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1703436

苯磺酸氨氯地平市场－全球产业规模、份额、趋势、机会和预测，按销售管道、最终用途、地区和竞争细分，2020-2030 年

Amlodipine Besylate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球苯磺酸氨氯地平市值为 6.9088 亿美元，预计到 2030 年将达到 12.1865 亿美元，预测期内年复合成长率(CAGR) 为 4.25%。该市场正在稳步增长，主要原因是高血压和心血管疾病的盛行率不断上升。氨氯地平贝磺酸盐是一种广泛使用的钙通道阻断剂，对于控制高血压和心绞痛至关重要，使其成为全球心血管治疗的基石。主要的市场驱动力是全球高血压发病率的上升，特别是在老年人口中。随着肥胖和糖尿病等与生活方式相关的健康状况的增加，对长期心血管治疗的需求也在增加。此外，随着新兴经济体医疗保健服务的扩大，越来越多的人得到诊断和治疗，这进一步刺激了对苯磺酸氨氯地平等廉价仿製药物的需求。

市场概览
预测期 2026-2030
2024年市场规模 6.9088亿美元
2030年市场规模 12.1865亿美元
2025-2030 年复合年增长率 4.25%
成长最快的领域 直接的
最大的市场 亚太

然而，市场竞争激烈，仿製药製造商众多，导致价格压力加大，利润率不断缩小。加强监管审查，特别是有关药品品质和製造标准的审查，也日益受到关注，特别是对于瞄准美国和欧盟市场的出口商而言。

主要市场驱动因素：

医疗保健产业的成长：

主要市场挑战：

转向联合疗法：

主要市场趋势：

高血压盛行率上升：

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球苯磺酸氨氯地平市场的影响

第五章：全球苯磺酸氨氯地平市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按销售管道（直接、间接）
    • 依最终用途（高血压、慢性稳定型心绞痛、血管痉挛性心绞痛、冠状动脉疾病、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美苯磺酸氨氯地平市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲苯磺酸氨氯地平市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区苯磺酸氨氯地平市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲苯磺酸氨氯地平市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东和非洲苯磺酸氨氯地平市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球苯磺酸氨氯地平市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Dr. Reddy's Laboratories Ltd.
  • Plasma Labs Pvt. Ltd
  • Changzhou Yabang Pharmaceutical Co., LTD.
  • DECLAN INDUSTRIES PVT. LTD
  • Kopalle Pharma Chemicals Private Limited
  • Graddy Pharmachem
  • PRUDENCE PHARM CHEM
  • Unichem Laboratories Ltd
  • Vineet Life Sciences Pvt. Ltd.
  • Lupin Limited

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28280

Global Amlodipine Besylate market was valued at USD 690.88 million in 2024 and is projected to reach USD 1,218.65 million by 2030, reflecting a compound annual growth rate (CAGR) of 4.25% during the forecast period. This market is experiencing steady growth, primarily driven by the increasing prevalence of hypertension and cardiovascular diseases. Amlodipine Besylate, a widely prescribed calcium channel blocker, is essential for managing high blood pressure and angina, making it a cornerstone of cardiovascular treatment worldwide. The primary market driver is the escalating global incidence of hypertension, particularly in aging populations. As lifestyle-related health conditions such as obesity and diabetes rise, the demand for long-term cardiovascular therapies is also growing. Additionally, with expanding healthcare access in emerging economies, more individuals are being diagnosed and treated, which further boosts demand for affordable generic alternatives like Amlodipine Besylate.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 690.88 Million
Market Size 2030USD 1218.65 Million
CAGR 2025-20304.25%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

However, the market is highly competitive, with numerous generic manufacturers, leading to price pressure and shrinking profit margins. Increased regulatory scrutiny, particularly concerning drug quality and manufacturing standards, is also a growing concern, especially for exporters targeting the U.S. and EU markets.

Key Market Drivers:

Growth in the Healthcare Sector:

The continued expansion of the global healthcare industry is a significant growth driver for the Amlodipine Besylate market. With the healthcare industry generating annual revenues exceeding USD 4 trillion, the pharmaceutical and biotechnology sectors contribute nearly USD 850 billion, while medical technology and diagnostics account for over USD 400 billion. As nations continue to invest in strengthening their healthcare systems-enhancing infrastructure, expanding access to medical services, and adopting advanced treatment protocols-the demand for antihypertensive medications such as Amlodipine Besylate is steadily increasing. Amlodipine Besylate remains a key treatment for high blood pressure and coronary artery disease, solidifying its position in both developed and emerging markets.

Key Market Challenges:

Shift Towards Combination Therapies:

A notable challenge in the Amlodipine Besylate market is the increasing preference among healthcare providers for fixed-dose combination (FDC) therapies. With a greater focus on improving patient compliance and achieving better therapeutic outcomes, many physicians are recommending combination treatments that pair Amlodipine with other antihypertensive agents like ACE inhibitors, ARBs, or diuretics. These combination therapies offer the convenience of a single pill, reduce pill burden, and often provide enhanced blood pressure control, making them more attractive from a clinical perspective. As a result, the demand for Amlodipine Besylate as a standalone treatment is gradually decreasing. This shift presents a challenge for manufacturers focused on monotherapy formulations, as they may experience a decline in market share and will need to adjust their strategies to include or co-market combination products. Additionally, the higher regulatory and development costs associated with fixed-dose combinations could create barriers for smaller market participants, intensifying competition.

Key Market Trends:

Rising Hypertension Prevalence:

The increasing global prevalence of hypertension is a critical trend propelling the growth of the Amlodipine Besylate market. The World Health Organization (WHO) reported in 2023 that 1.28 billion adults aged 30 to 79 suffer from hypertension, with two-thirds of these individuals residing in low- and middle-income countries. A key global health goal is to reduce the prevalence of hypertension by 33% from 2010 to 2030. Often called the "silent killer," hypertension is one of the most widespread chronic conditions and a major risk factor for cardiovascular diseases, strokes, and kidney problems. The growing number of hypertension diagnoses, particularly in low- and middle-income nations, is significantly boosting the demand for effective antihypertensive treatments like Amlodipine Besylate. This trend is driven by demographic and lifestyle factors, including aging populations, sedentary behaviors, poor diets, rising obesity rates, and increased stress. As awareness and diagnostic capabilities improve, more individuals are being screened and treated, contributing to a larger patient base reliant on long-term pharmacological interventions.

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • Plasma Labs Pvt. Ltd
  • Changzhou Yabang Pharmaceutical Co., LTD.
  • DECLAN INDUSTRIES PVT. LTD
  • Kopalle Pharma Chemicals Private Limited
  • Graddy Pharmachem
  • PRUDENCE PHARM CHEM
  • Unichem Laboratories Ltd
  • Vineet Life Sciences Pvt. Ltd.
  • Lupin Limited

Report Scope

In this report, the Global Amlodipine Besylate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amlodipine Besylate Market, By Sales Channel:

  • Direct
  • Indirect

Amlodipine Besylate Market, By End Use:

  • Hypertension
  • Chronic Stable Angina
  • Vasospastic Angina
  • Coronary Artery Disease
  • Others

Amlodipine Besylate Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amlodipine Besylate Market.

Available Customizations:

Global Amlodipine Besylate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Amlodipine Besylate Market

5. Global Amlodipine Besylate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hypertension, Chronic Stable Angina, Vasospastic Angina, Coronary Artery Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Amlodipine Besylate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Amlodipine Besylate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Amlodipine Besylate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Amlodipine Besylate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Amlodipine Besylate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Amlodipine Besylate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Amlodipine Besylate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Amlodipine Besylate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Amlodipine Besylate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Amlodipine Besylate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Amlodipine Besylate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Amlodipine Besylate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Amlodipine Besylate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Amlodipine Besylate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Amlodipine Besylate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Amlodipine Besylate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Amlodipine Besylate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Amlodipine Besylate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Amlodipine Besylate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Amlodipine Besylate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Amlodipine Besylate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Amlodipine Besylate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Amlodipine Besylate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Amlodipine Besylate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Amlodipine Besylate Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Plasma Labs Pvt. Ltd
  • 15.3. Changzhou Yabang Pharmaceutical Co., LTD.
  • 15.4. DECLAN INDUSTRIES PVT. LTD
  • 15.5. Kopalle Pharma Chemicals Private Limited
  • 15.6. Graddy Pharmachem
  • 15.7. PRUDENCE PHARM CHEM
  • 15.8. Unichem Laboratories Ltd
  • 15.9. Vineet Life Sciences Pvt. Ltd.
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer